UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
Olympus-backed PAI Pharma buys injectables maker Nexus Pharmaceuticals
PAI Pharma, an Olympus Partners portfolio company known for oral liquid medicines, has acquired Nexus Pharmaceuticals, which develops and sells injectable drugs for critical care, oncology and other hospital settings. Nexus brings more than 20 hospital injectable products. Terms were not disclosed.
Why it matters: Following its Nivagen acquisition, PAI is building scale in U.S. hospital and sterile injectable markets.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →